COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
The guidance explains when clinical laboratories can begin testing for SARS-CoV-2 after submitting the CMS-116 application for a CLIA Certificate of Waiver.
Guidance changed for three questions about CLIA standards pertaining to COVID-19 testing.
The FDA continues to accelerate at-home COVID-19 test accessibility for consumers with this, the third emergency use authorization for a fully at-home test.
Insight into the federal payments that clinical laboratories received after CMS expanded its Accelerated and Advance Payment (AAP) Program to increase cash flow to Medicare providers and suppliers impacted by the 2019 novel coronavirus (COVID-19) public health emergency.
Explanation of the range of new guidance for approaching COVID-19 testing in nursing homes.
Convalescent plasma titers can now be qualified using the Mount Sinai COVID-19 ELISA IgG Antibody Test.
The guidance explains when clinical laboratories can begin testing for SARS-CoV-2 after submitting the CMS-116 application for a CLIA Certificate of Waiver.
Guidance changed for three questions about CLIA standards pertaining to COVID-19 testing.
The FDA continues to accelerate at-home COVID-19 test accessibility for consumers with this, the third emergency use authorization for a fully at-home test.
Insight into the federal payments that clinical laboratories received after CMS expanded its Accelerated and Advance Payment (AAP) Program to increase cash flow to Medicare providers and suppliers impacted by the 2019 novel coronavirus (COVID-19) public health emergency.
Explanation of the range of new guidance for approaching COVID-19 testing in nursing homes.
Convalescent plasma titers can now be qualified using the Mount Sinai COVID-19 ELISA IgG Antibody Test.
